BR112016001114A2 - membros da família tnf direcionados modificados - Google Patents

membros da família tnf direcionados modificados

Info

Publication number
BR112016001114A2
BR112016001114A2 BR112016001114-7A BR112016001114A BR112016001114A2 BR 112016001114 A2 BR112016001114 A2 BR 112016001114A2 BR 112016001114 A BR112016001114 A BR 112016001114A BR 112016001114 A2 BR112016001114 A2 BR 112016001114A2
Authority
BR
Brazil
Prior art keywords
cytokine
modified
tnf superfamily
family members
tnf family
Prior art date
Application number
BR112016001114-7A
Other languages
English (en)
Other versions
BR112016001114B1 (pt
Inventor
Tavernier Jan
Bultinck Jennyfer
Peelman Frank
Uzé Gilles
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of BR112016001114A2 publication Critical patent/BR112016001114A2/pt
Publication of BR112016001114B1 publication Critical patent/BR112016001114B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

a presente invenção refere-se a uma citocina modificada da superfamília do tnf, com atividade reduzida ao seu receptor, em que a referida citocina modificada é entregue especificamente às células alvo. preferencialmente, a referida citocina modificada é uma variante de cadeia simples da superfamília de tnf, ainda mais preferencialmente, uma ou mais das cadeias transportando uma ou mais mutações, resultando em uma baixa afinidade para o receptor, em que a referida citocina mutante é especificamente entregue às células alvo. o direcionamento é realizado por meio da fusão da citocina modificada da superfamília do tnf a uma fração de direcionamento, de preferência, um anticorpo ou molécula de anticorpo semelhante. a invenção refere-se ainda ao uso de tal citocina modificado alvo da superfamília de tnf no tratamento de doenças.
BR112016001114-7A 2013-07-19 2014-07-18 Composição compreendendo uma proteína de fusão e uso da referida composição BR112016001114B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306046.7 2013-07-19
EP13306046 2013-07-19
PCT/EP2014/065554 WO2015007903A1 (en) 2013-07-19 2014-07-18 Targeted modified tnf family members

Publications (2)

Publication Number Publication Date
BR112016001114A2 true BR112016001114A2 (pt) 2018-01-23
BR112016001114B1 BR112016001114B1 (pt) 2023-02-14

Family

ID=48874234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016001114-7A BR112016001114B1 (pt) 2013-07-19 2014-07-18 Composição compreendendo uma proteína de fusão e uso da referida composição

Country Status (14)

Country Link
US (6) US9914759B2 (pt)
EP (1) EP3021865B1 (pt)
JP (1) JP6595988B2 (pt)
KR (1) KR102268688B1 (pt)
CN (1) CN105492017B (pt)
AU (1) AU2014291961B2 (pt)
BR (1) BR112016001114B1 (pt)
CA (1) CA2918363C (pt)
DK (1) DK3021865T3 (pt)
ES (1) ES2686668T3 (pt)
IL (1) IL243509B (pt)
MX (1) MX370565B (pt)
SG (1) SG11201600168UA (pt)
WO (1) WO2015007903A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3371311B1 (en) * 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
JP7166923B2 (ja) 2016-02-05 2022-11-08 オリオニス バイオサイエンシズ ビーブイ 標的療法剤およびその使用
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
WO2017151940A2 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3426687A1 (en) * 2016-03-07 2019-01-16 VIB vzw Cd20 binding agents and uses thereof
JP2019507762A (ja) * 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
CN109563141A (zh) * 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
NZ754407A (en) 2016-11-09 2023-01-27 Philogen Spa Il2 and tnf mutant immunoconjugates
CA3043630A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN111010875B (zh) 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
US11498966B2 (en) 2017-08-09 2022-11-15 Orionis Biosciences Inc. PD-1 and PD-L1 binding agents
KR20200085781A (ko) 2017-10-20 2020-07-15 프레드 헛친슨 켄서 리서치 센터 선택된 항체를 발현하도록 유전자 변형된 b 세포를 생산하기 위한 시스템 및 방법
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
WO2020198654A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
JP2023526723A (ja) 2020-05-12 2023-06-23 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2055445T3 (es) 1989-08-22 1994-08-16 Immunex Corp Proteinas de fusion que comprenden gm-csf e il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
DK2604693T3 (en) 2008-07-21 2016-05-30 Apogenix Gmbh Single-chain TNFSF molecules
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
AU2010294249A1 (en) 2009-09-10 2012-05-03 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
US9534056B2 (en) * 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
US9492562B2 (en) 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
JP6195855B2 (ja) 2012-03-03 2017-09-13 イミュンジーン，インコーポレーテッド 工学的に作製した抗体−インターフェロン変異体融合分子
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations

Also Published As

Publication number Publication date
US10035835B2 (en) 2018-07-31
US20180170989A1 (en) 2018-06-21
US20190367575A1 (en) 2019-12-05
ES2686668T3 (es) 2018-10-19
KR102268688B1 (ko) 2021-06-24
MX370565B (es) 2019-12-17
IL243509A0 (en) 2016-03-31
SG11201600168UA (en) 2016-02-26
US10407480B2 (en) 2019-09-10
IL243509B (en) 2018-12-31
US20220324929A1 (en) 2022-10-13
CN105492017B (zh) 2020-12-01
CA2918363A1 (en) 2015-01-22
KR20160108294A (ko) 2016-09-19
DK3021865T3 (en) 2018-09-17
CA2918363C (en) 2021-12-14
US9914759B2 (en) 2018-03-13
AU2014291961B2 (en) 2018-09-27
US20180298074A1 (en) 2018-10-18
MX2016000722A (es) 2016-09-07
JP6595988B2 (ja) 2019-10-23
WO2015007903A1 (en) 2015-01-22
EP3021865B1 (en) 2018-06-13
EP3021865A1 (en) 2016-05-25
US11396532B2 (en) 2022-07-26
US10787493B2 (en) 2020-09-29
CN105492017A (zh) 2016-04-13
JP2016531103A (ja) 2016-10-06
US20160159874A1 (en) 2016-06-09
US20200262884A1 (en) 2020-08-20
BR112016001114B1 (pt) 2023-02-14
AU2014291961A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112016001128A2 (pt) membros da família il-1 modificados direcionados
BR112018003535A2 (pt) receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112016010166A2 (pt) métodos para usar interleucina-10 para tratar doenças e distúrbios
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
CR20150200A (es) Derivados de exendina-4 como agonistas duales de glp1/glucacón
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
BR112019025381A2 (pt) Uso de bactérias de ácido láctico para tratar ou prevenir pelo menos uma dentre depressão pós-natal e ansiedade pós-natal
BR112015014510A2 (pt) agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112015013700A8 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
BR112013029269A8 (pt) combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2
BR112012006035A2 (pt) epratuzumab para uso no tratamento de uma doença autoimune ou inflamatória, e, kit
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
BR112016002462A8 (pt) Métodos para melhorar os sintomas da asma usando benralizumabe
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: VIB VZW (BE) ; UNIVERSITEIT GENT (BE) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER (FR) ; UNIVERSITE MONTPELLIER (FR)

Owner name: VIB VZW (BE) ; UNIVERSITEIT GENT (BE) ; CENTRE NAT

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2014, OBSERVADAS AS CONDICOES LEGAIS